Bayer Technology Services and Xytel market microreaction technology
Flexible and high performance pilot plants for the oil & gas, chemical and pharmaceutical industries
Leverkusen, July 2008 – Ehrfeld Mikrotechnik BTS GmbH (EMB), a subsidiary of Bayer Technology Services GmbH, and Xytel Inc. have signed a production and marketing agreement to introduce innovative microreaction technology in pilot plants for the oil & gas, chemical and pharmaceutical industries. Modular microreaction systems by EMB increase the flexibility and performance of pilot plants, which are widely used to open new reaction routes and to reduce energy and raw material consumption.
EMB is one of the leading providers of microreaction technology related services and products. EMB provides micromixer, micro heat exchanger and microreactor units in a variety of materials and for a wide range of flowrates. The EMB systems allow easy disassembly which can be crucial in the initial stages of process development. Furthermore EMB is able to customize on demand. Microreactors inherently allow fast heat and mass transfer which in turn translates to better control, safer operation and shorter residence time.
Xytel is a leading provider of skid mounted packages for the fine chemical and petrochemical industry. Xytel excels in understanding customer needs and customizing their skid mounted units to suit customer requirements.
An integrated system that consists of customized EMB microsystems in a Xytel skid mounted unit has been successfully tested. This system allowed studie in the pilot scale of potentially hazardous chemicals in a controlled and safe manner.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.